ArticleDrugs in context2024

Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study.

Tiago Torres et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.